| For: | Bellanti F, Vendemiale G. Coronavirus disease 2019 and non-alcoholic fatty liver disease. World J Hepatol 2021; 13(9): 969-978 [PMID: 34630869 DOI: 10.4254/wjh.v13.i9.969] |
|---|---|
| URL: | https://www.wjgnet.com/1007-9327/full/v13/i9/969.htm |
| Number | Citing Articles |
| 1 |
Mingli Shen, Qingping Shi, Shuang Gao, Beiyan Chen, Jieru Han. Exploring the Molecular Mechanism of Cinnamaldehyde Intervening in Ochratoxin A-Induced Type 2 Diabetes Mellitus and Non-Alcoholic Fatty Liver Disease Comorbidity: An Integrated Approach Based on Network Pharmacology, Network Toxicology and Molecular Docking. Pharmaceuticals 2026; 19(8) doi: 10.3390/ph19081283
|
| 2 |
Dafeng Liu, Yongli Zheng, Jun Kang, Dongmei Wang, Lang Bai, Yi Mao, Guifang Zha, Hong Tang, Renqing Zhang. Not Only High Number and Specific Comorbidities but Also Age Are Closely Related to Progression and Poor Prognosis in Patients With COVID-19. Frontiers in Medicine 2022; 8 doi: 10.3389/fmed.2021.736109
|
| 3 |
Andrew J. Krentz. Cardiovascular Endocrinology and Metabolism. 2023; doi: 10.1016/B978-0-323-99991-5.00010-3
|
| 4 |
Ka Shing Cheung, Lok Ka Lam, Rex Wan Hin Hui, Xianhua Mao, Ruiqi R Zhang, Kwok Hung Chan, Ivan FN Hung, Wai Kay Seto, Man-Fung Yuen. Effect of moderate-to-severe hepatic steatosis on neutralising antibody response among BNT162b2 and CoronaVac recipients. Clinical and Molecular Hepatology 2022; 28(3) doi: 10.3350/cmh.2022.0082
|
| 5 |
Dhanvee Balaji, Ranjith Balakrishnan, Dhasarathdev Srinivasan, Rajasekaran Subbarayan, Rupendra Shrestha, Nityanand Srivastava, Ankush Chauhan. The Impact of SARS-CoV-2 on Liver Diseases and Potential Phytochemical Treatments. Infectious Microbes and Diseases 2024; 6(4) doi: 10.1097/IM9.0000000000000161
|